Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens

@article{Alehagen2015ReducedCM,
  title={Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens},
  author={Urban Alehagen and Jan Olav Aaseth and Peter Johansson},
  journal={PLoS ONE},
  year={2015},
  volume={10}
}
Background Selenium and coenzyme Q10 are important antioxidants in the body. As the intake of selenium is low in Europe, and the endogenous production of coenzyme Q10 decreases as age increases, an intervention trial using selenium and coenzyme Q10 for four years was performed. As previously reported, the intervention was accompanied by reduced cardiovascular mortality. The objective of the present study was to analyze cardiovascular mortality for up to 10 years after intervention, to evaluate… 

Figures and Tables from this paper

Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly

A 12-year follow-up of a group of healthy elderly participants that were supplemented with selenium and coenzyme Q10 for four years validated the results obtained in the 10-year evaluation and observed a significantly reduced risk for CV mortality in this group, as well as in subgroups of patients with diabetes, hypertension, ischemic heart disease or impaired functional capacity.

Significant changes in circulating microRNA by dietary supplementation of selenium and coenzyme Q10 in healthy elderly males. A subgroup analysis of a prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens

Significant differences were found in expression of more than 100 different microRNAs with up to 4 fold differences as a result of the intervention of selenium and coenzyme Q10 combined.

Improved cardiovascular health by supplementation with selenium and coenzyme Q10: applying structural equation modelling (SEM) to clinical outcomes and biomarkers to explore underlying mechanisms in a prospective randomized double-blind placebo-controlled intervention project in Sweden

Structural Equation Modelling (SEM) was used to investigate the statistical inter-relationships between biomarkers related to inflammation, oxidative stress, insulin-like growth factor 1, expression of microRNA, fibrosis, and endothelial dysfunction and their impact on the clinical effects.

Supplementation with Selenium and Coenzyme Q10 Reduces Cardiovascular Mortality in Elderly with Low Selenium Status. A Secondary Analysis of a Randomised Clinical Trial

This is a small study, but it presents interesting data, and more research on the impact of lower selenium intake than recommended is therefore warranted.

Selenium and Coenzyme Q10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial

Preservation of LTL after selenium and coenzyme Q10 supplementation associated with reduced cardiovascular mortality and subjects suffering future death presented with significantly shorter LTL at 42 months than survivors.

Less fibrosis in elderly subjects supplemented with selenium and coenzyme Q10—A mechanism behind reduced cardiovascular mortality?

Observations might indicate that reduced fibrosis precedes the reported improvement in cardiac function, thereby explaining some of the positive clinical effects caused by the Intervention, 44(2):137-147, 2018.

Increased SIRT1 Concentration Following Four Years of Selenium and Q10 Intervention Associated with Reduced Cardiovascular Mortality at 10-Year Follow-Up—Sub-Study of a Previous Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial

The increased Sirtuin1 concentration after the SeQ10 intervention associated with reduced CV mortality, partly mediated via miR-1303a-3p, suggests that SIRT1 is an additional mediator of the intervention, preventing vascular ageing.

Selenium Concentrations and Mortality Among Community-Dwelling Older Adults: Results from ilSIRENTE Study

Low serum levels of selenium are associated with reduced survival in elderly, independently of age and other clinical and functional variables.

[Coenzyme Q-10 in the treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: systematic review and meta-analysis].

The meta-analysis confirmed the beneficial effect of coenzyme Q10 on the prognosis of patients with chronic heart failure receiving the recommended basic therapy.
...

Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

CRP and sP-selectin showed significant changes reflecting effects on inflammation and atherosclerosis in those given selenium and coenzyme Q10 combined, and a reduced cardiovascular mortality could be demonstrated in the active group, irrespective of biomarker level.

Relatively high mortality risk in elderly Swedish subjects with low selenium status

The mean serum Se concentration in an elderly Swedish population was 67.1 μg/l, which is below the physiological saturation level for several selenoprotein enzymes, which may suggest the value of modest Se supplementation in order to improve the health of the Swedish population.

Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial

Coenzyme Q10 supplementation at 300 mg/d significantly enhances antioxidant enzymes activities and lowers inflammation in patients who have CAD during statins therapy.

Serum selenium and prognosis in cardiovascular disease: results from the AtheroGene study.

Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial.

Despite the documented antioxidant and chemopreventive properties of selenium, studies of selenium intake and supplementation and cardiovascular disease have yielded inconsistent findings. The

Serum selenium predicts levels of F2-isoprostanes and prostaglandin F2α in a 27 year follow-up study of Swedish men

High concentrations of s–Se predict reduced levels of oxidative stress and subclinical COX-mediated (but not cytokine-mediated) inflammation in a male population of Swedish men.

Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial.

Plasma selenoprotein P is a useful biomarker of status in populations with relatively low selenium intakes because it responds to different dietary forms of seenium.

Selenium intake and cardiovascular risk: what is new?

Current evidence is insufficient to support a protective role for selenium in cardiovascular prevention and large high-quality randomized controlled trials and observational studies are needed across populations with different levels of selenum intake.

Low plasma selenium concentrations and mortality among older community-dwelling adults: the InCHIANTI Study

Low plasma selenium levels at enrollment and all-cause mortality over a 6-year period among participants in the InCHIANTI study may be an independent predictor of mortality among older adults living in the community.